CrystalGenomics Obtains Japanese Patent for 'Aselex' Combination Drug

[Asia Economy Reporter Lee Chun-hee] CrystalGenomics announced on the 17th that it has obtained a Japanese patent for ‘CG-650,’ a combination drug under development that includes 'Aselex (active ingredient: Polmacoxib)' and 'Tramadol.' The patent is titled ‘Pharmaceutical composition for acute and chronic pain treatment containing Polmacoxib and Tramadol.’

This formulation patent refers to a patent on the buffer agents additionally used to stabilize the substance (drug). Securing a formulation patent is essential to gain approval from pharmaceutical regulatory authorities in each country and subsequently enter the respective markets.

Additionally, by using a more stable Aselex raw material, it has become possible to develop various formulations, including oral formulations that can improve patient compliance. Combination drugs are pharmaceuticals that improve the drawbacks of original drugs through various technologies such as formulation changes and salt modifications. They are safer, more effective, and more convenient to take than existing products, and by holding patent rights, they can secure competitiveness in the global market.

This patent is valid until June 8, 2038. During this period, other companies will be fundamentally prevented from manufacturing using the same method.

A CrystalGenomics official stated, “By advancing the development of the Aselex combination drug as part of our Life Cycle Management strategy, we aim to expand indications, extend the period of exclusive sales, and broaden the market.”